Merck, operating under the trade name MSD in the European Union, announced today that it has launched Samsung Bioepis’ biosimilar trastuzumab, Ontruzant, in the United Kingdom.
Merck, operating under the trade name MSD in the European Union, announced today that it has launched Samsung Bioepis’ biosimilar trastuzumab, Ontruzant, in the United Kingdom.
The biosimilar, also known as SB3, references Roche’s Herceptin, and is approved to treat early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The brand-name Herceptin, approved in the European Union in 2000, is among the top-selling drugs in the global marketplace, having earned $6.75 billion in sales in 2016. Until today, the reference drug has remained unchallenged by biosimilar competition in Europe.
Mark Verrill, MA, MB, FRCP, head of the department of medical oncology at the Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust, said in a statement, “This is good news for so many cancer patients and the NHS. The launch of biosimilar trastuzumab provides a high-quality treatment alternative for patients, while offering significant potential savings for the NHS. The biggest category of medicines in oncology is monoclonal antibodies, and the introduction of biosimilars such as trastuzumab could provide a substantial cost saving.”
Denise Blake, MPharm, the senior lead clinical pharmacist at Newcastle Hospitals, added that, while the introduction of the biosimilar into the NHS has the potential to produce a significant cost savings to the health system, "Close collaboration between oncologists, pharmacists and nursing staff is required to ensure a seamless introduction into routine clinical practice."
The European Commission granted a marketing authorization for Ontruzant in November 2017, allowing the biosimilar to be sold in the European Union and the European Economic Area (comprising Norway, Iceland, and Liechtenstein). The authorization followed a September 2017 positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Samsung Bioepis has also filed for US regulatory review for the drug; in December 2017, the company announced that it has submitted a Biologics License Application for the biosimilar to the FDA. If eventually approved, the drug will be commercialized in the United States by Merck. Earlier this week, the biosimilar launched in the Republic of Korea, where it is commercialized by Daewoong Pharmaceutical under the brand name Samfenent.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.